NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

BlackRock International V.I. Fund posted a return of -4.75% (Class I shares) for the fourth quarter of 2024. Read more here.

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

BlackRock Global Dividend Fund posted returns of -4.66% (Institutional shares) and -4.64% (Investor A shares, without sales ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" or "the Company")  for violations of §§10(b) and 20(a) ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...